|
Getting your Trinity Audio player ready...
|
DALLAS, Texas, Nov. 16, 2026 – ZenaTech, Inc. (Nasdaq: ZENA) edged higher early Monday after a sharp pullback, as investors weighed a new medical drone initiative against the costs of the company’s rapid expansion. Shares traded near $0.61, up about 1.8% in early trading, after falling 5% Friday to $0.5953. The stock closed at $2.13 on Aug. 13, when it reached an intraday high of $2.19. Monday’s move was an early bounce after three consecutive down sessions.
ZenaDrone moves into military medical logistics
ZenaTech said Nov. 12 that its ZenaDrone subsidiary signed a memorandum of understanding with Rattler Medical Inc. to develop a drone-based system for delivering temperature-controlled blood to military medical personnel. The companies plan to combine ZenaDrone’s cargo aircraft with Rattler Medical’s blood transport containers, with a flying prototype and demonstrations targeted for summer 2027. The project addresses a specific logistics problem in trauma care: getting blood to medics quickly while maintaining the required temperature in transit.
The agreement gives ZenaDrone a concrete development milestone in medical logistics. A successful demonstration would give prospective military customers a system to evaluate. Commercial adoption and any procurement awards would come in later stages.
Revenues Continue Upward Growth Pattern
ZenaTech’s disclosures show continued revenue growth through the selloff. The company reported 425% year-over-year revenue growth in the first half of 2026 and estimated preliminary third-quarter revenue of US$9.5 million to US$10.5 million, implying 44% to 59% sequential growth. Its acquisition-led Drone as a Service business, which serves markets such as land surveying and inspections, accounted for 93% of first-half revenue.
The filings also give investors reasons to weigh that growth carefully. ZenaTech reported a first-half net loss of approximately US$34.8 million and expanded its at-the-market equity offering to US$150 million in October, creating room for additional share issuance. The public record leaves the precise drivers of the selloff uncertain. For the early bounce to develop into a sustained reversal, a first test would be whether ZENA can hold above Friday’s $0.5615 low and reclaim its $0.70 close from Nov. 10.
Other Nasdaq stocks to watch after pullbacks
Alongside ZenaTech (NASDAQ: ZENA), ImmunityBio (NASDAQ: IBRX), Quantum-Si (NASDAQ: QSI), PDS Biotechnology (NASDAQ: PDSB), Peraso (NASDAQ: PRSO) and Global Mofy AI (NASDAQ: GMM) were also trading below recent highs. Those prior highs give investors reference points for gauging any recovery.
About ZenaTech, ZenaDrone and Rattler Medical
ZenaTech, Inc. (Nasdaq: ZENA) is a technology company specializing in AI-powered autonomous drones, Drone as a Service (DaaS) and enterprise software. With operations across North America, Europe, the Middle East, Asia and Australia, ZenaTech is pursuing an acquisition-led DaaS strategy to digitize and automate services such as land surveying and inspections while building a recurring revenue base. The company serves commercial, government and defense markets and invests in research and development involving advanced AI autonomy, drone swarms and quantum computing. Its manufacturing subsidiary, ZenaDrone, develops autonomous systems that integrate machine learning, predictive analytics and advanced computing. Its portfolio under development includes the ZenaDrone 1000 for intelligence, surveillance, reconnaissance and specialized cargo, the IQ Nano for indoor inventory and security, the IQ Square for outdoor inspections and maintenance, the IQ Quad for land surveying, the IQ Aqua for underwater applications and the IQ Octo for precision agriculture. ZenaDrone operates manufacturing facilities in Arizona, Dubai and Taiwan and is developing maritime counter-drone systems. Rattler Medical Inc., based in Boise, Idaho, develops and manufactures temperature-controlled containers designed to store and transport blood in remote and austere environments. Founded by U.S. Army combat medic veteran Donald Young, the company aims to help military and emergency medical personnel bring blood closer to patients.
About The Street Reports
The Street Reports (TSR) is a financial media awareness platform focused on emerging-growth, small-cap, micro-cap and nano-cap companies. The Street Reports publishes and distributes market-focused content across financial news, media and digital channels, providing companies with expanded visibility and exposure to a broad audience of readers and market participants.
